NASDAQ · BJDX
Healthcare · Medical - Devices
$2.21
Up+$0.08 (+3.62%)
Updated Nov 4, 2026, 11:35 PM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BJDX
1M range · 0 trading sessions · Daily adjusted prices
BJDX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning BJDX.
Company
Market Activity
Research & News
BJDX research
Company profile and research snapshot.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from 'sample-to-result' to help medical professionals make earlier and better triage/treatment decisions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2023 | Dawson James | Neutral | — |
| Jan 12, 2022 | Dawson James | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 21, 2026
Bluejay Diagnostics, Inc. (NASDAQ:BJDX), a medical diagnostics company developing rapid, near-patient diagnostic technologies for critical care, today announced the successful completion of patient enrollment in its
Benzinga · Jul 20, 2026
Gainers Advanced Biomed (NASDAQ:ADVB) shares rose 24.1% to $6.24 during Monday's pre-market session. The market value of their outstanding shares is at $8.2 million. Barinthus Biotherapeutics (NASDAQ:BRNS) shares
Benzinga · Jul 17, 2026
Gainers iTonic Holdings (NASDAQ:ITOC) stock increased by 8.1% to $0.3 during Friday's after-market session. The market value of their outstanding shares is at $5.1 million. Advanced Biomed (NASDAQ:ADVB) shares
Benzinga · Mar 6, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BJDX.
